1 Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 2011, 61: 212-236
[2]
2 Hidalgo M. Pancreatic cancer. N Engl J Med, 2010, 362: 1605-1617？？
[3]
3 Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med, 2010, 7: e1000267？？
[4]
4 Kim B J, Lee K T, Moon T G, et al. How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? Dig Liver Dis, 2009, 41: 364-369
[5]
5 Duffy M J, Sturgeon C, Lamerz R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol, 2010, 21: 441-447？？
[6]
6 Pan B, Zhao Y P, Ning L, et al. Proteomic analysis of membrane proteins of endomembrane system in human pancreatic cancer cell (in Chinese). Zhonghua Wai Ke Za Zhi, 2010, 48: 461-465
[7]
7 Wang W B, Zhao Y P, Liao Q, et al. Candidate immunogenic membrane antigens of human pancreatic cancer (in Chinese). Zhonghua Wai Ke Za Zhi, 2010, 48: 1412-1415
[8]
8 Dempster E L, Mill J, Craig I W, et al. The quantification of COMT mRNA in post mortem cerebellum tissue: diagnosis, genotype, methylation and expression. BMC Med Genet, 2006, 7: 10
[9]
9 Wu W M, Zhao Y P, Liao Q, et al. The expression of catechol O-methyltransferase gene in colorectal cancer (in Chinese). Zhonghua Wai Ke Za Zhi, 2010, 48: 535-538
[10]
10 Thompson P A, Shields P G, Freudenheim J L, et al. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res, 1998, 58: 2107-2110
[11]
11 Ahsan H, Chen Y, Whittemore A S, et al. A family-based genetic association study of variants in estrogen-metabolism genes COMT and CYP1B1 and breast cancer risk. Breast Cancer Res Treat, 2004, 85: 121-131？？
[12]
12 Ji Y, Olson J, Zhang J, et al. Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res, 2008, 68: 5997-6005？？
[13]
13 Hirata H, Hinoda Y, Okayama N, et al. COMT polymorphisms affecting protein expression are risk factors for endometrial cancer. Mol Carcinog, 2008, 47: 768-774？？
[14]
14 Freedman N D, Ahn J, Hou L, et al. Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer. Carcinogenesis, 2009, 30: 71-77
[15]
15 Kahlert C, Bergmann F, Beck J, et al. Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. BMC Cancer, 2011, 11: 275？？
[16]
16 Huber J C, Schneeberger C, Tempfer C B. Genetic modeling of estrogen metabolism as a risk factor of hormone-dependent disorders. Maturitas, 2002, 41: S55-S64？？
[17]
17 Cavalieri E L, Stack D E, Devanesan P D, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA, 1997, 94: 10937-10942
[18]
18 Yager J D, Liehr J G. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol, 1996, 36: 203-232？？
[19]
19 Pribluda V S, Gubish E R Jr., Lavallee T M, et al. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev, 2000, 19: 173-179
[20]
20 Qanungo S, Basu A, Das M, et al. 2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells. Oncogene, 2002, 21: 4149-4157？？
[21]
21 Kreiger N, Lacroix J, Sloan M. Hormonal factors and pancreatic cancer in women. Ann Epidemiol, 2001, 11: 563-567？？
[22]
22 Duell E J, Holly E A. Reproductive and menstrual risk factors for pancreatic cancer: a population-based study of San Francisco Bay Area women. Am J Epidemiol, 2005, 161: 741-747？？
[23]
23 Karhunen T, Tilgmann C, Ulmanen I, et al. Distribution of catechol-O-methyltransferase enzyme in rat tissues. J Histochem Cytochem, 1994, 42: 1079-1090？？
[24]
24 Theve N O, Pousette A, Carlstrom K. Adenocarcinoma of the pancreas--a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol, 1983, 9: 193-197
[25]
25 Tonnesen K, Kamp-Jensen M. Antiestrogen therapy in pancreatic carcinoma: a preliminary report. Eur J Surg Oncol, 1986, 12: 69-70
[26]
26 Keating J J, Johnson P J, Cochrane A M, et al. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer, 1989, 60: 789-792？？
[27]
27 Iwao K, Miyoshi Y, Ooka M, et al. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in human pancreatic cancers by real-time polymerase chain reaction. Cancer Lett, 2001, 170: 91-97？？
[28]
28 Konduri S, Schwarz R E. Estrogen receptor beta/alpha ratio predicts response of pancreatic cancer cells to estrogens and phytoestrogens. J Surg Res, 2007, 140: 55-66？？
